Orion Oyj (HEL:ORNBV)

Market Cap	13.82B +44.1%
Revenue (ttm)	2.18B +33.7%
Net Income	658.70M +110.3%
EPS	4.68 +110.1%
Shares Out	140.37M
PE Ratio	21.03
Forward PE	17.48
Dividend	1.80 (1.83%)
Ex-Dividend Date	Oct 19, 2026

Volume	191,675
Open	94.45
Previous Close	95.95
Day's Range	94.00 - 99.60
52-Week Range	56.50 - 99.40
Beta	0.28
Analysts	Buy
Price Target	85.33 (-13.28%)
Earnings Date	Oct 28, 2026

About Orion Oyj

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. It offers pharmaceutical products, which includes Nubeqa for the treatment of prostate cancer; Entacapone, Stalevo, Comtess, and Comtan to treat Parkinson's disease; Burana for inflammatory pain; Divina series for menopausal symptoms; Simdax for acute decompensated heart failure; Fareston for breast cancer; Quetiapine products for antipsychoti...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1917
• Employees: 4,000
• Stock Exchange: Nasdaq Helsinki
• Ticker Symbol: ORNBV

Financial Performance

In 2025, Orion Oyj's revenue was 1.89 billion, an increase of 22.50% compared to the previous year's 1.54 billion. Earnings were 500.30 million, an increase of 51.65%.

Analyst Summary

According to 6 analysts, the average rating for ORNBV stock is "Buy." The 12-month stock price target is €85.33, which is a decrease of -13.28% from the latest price.

Price Target

€85.33

(-13.28% downside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence and QUODD

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by QUODD.

Last checked:

Oct 29, 2026

Data Sources Report a data error